Other Clinical Trial - A Multicenter Prospective Study of NCT04320992

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Details — Status: Recruiting

The purpose of this study is to determine the indicative value of "high risk" molecular typing in patients with adult T lymphoblastic lymphoma

Recruitment information / eligibility
Status	Recruiting
Enrollment	207
Est. completion date	March 2023
Est. primary completion date	March 2023
Accepts healthy volunteers
Gender	All
Age group	18 Years and older
Eligibility	Inclusion Criteria: - biopsy proved T lymphoblastic lymphoma - newly diagnosed patients Exclusion Criteria: - patients with biopsy samples unavailable

Locations
Country	Name	City	State
China	Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University,	Guangzhou

Sponsors *(1)*
Lead Sponsor	Collaborator
Sun Yat-sen University

China,

Outcome
Type	Measure	Description	Time frame	Safety issue
Primary	progression free survival		3-years